Digestive Infection May Be Hidden Trigger for Celiac Disease, New Research Suggests
A groundbreaking study from the University of León (ULE) proposes that a digestive infection could be a key, previously overlooked factor in the development of active celiac disease, potentially revolutionizing treatment approaches beyond the current reliance on a gluten-free diet. The project, titled ‘Role of infection as a trigger for active celiac disease,’ has been awarded €18,000 by the Association of Celiacs and Gluten Sensitives to further investigate this promising new avenue of research.
The research, led by ULE scientists Nicolás Navasa and Leander Rodríguez, is being lauded for its potential to reshape understanding of this autoimmune disorder. The team expressed their gratitude for the award, noting its significance as a highly competitive honor funded entirely by contributions from individuals affected by celiac disease and gluten sensitivity. This direct community support underscores the vital connection between biomedical research and the real-world needs of patients.
Beyond Gluten: Unraveling the Root Cause of Intestinal Damage
Current understanding of celiac disease centers on an autoimmune response to gluten, but researchers have long recognized that gluten alone doesn’t fully explain the extent of intestinal damage observed in patients. While autoimmunity against gluten is a necessary component, it doesn’t completely account for the characteristic intestinal villous atrophy – the flattening of the small intestine’s lining – seen in active cases.
The ULE team hypothesizes that mechanisms independent of gluten trigger this atrophy, and these mechanisms have remained elusive until now. Their research explores whether a digestive infection could act as a “final trigger,” activating immune cells responsible for tissue damage. This suggests a more complex interplay of factors than previously understood.
Identifying Potential Culprits in Patient Biopsies
Researchers have analyzed biopsies from 120 patients participating in the National Epidemiological Plan for Celiac Disease, in collaboration with University Hospital of León and the hospital in Terrassa. This analysis revealed the presence of two intracellular pathogens exclusively in the inflamed mucosa of patients experiencing active celiac disease. These findings position these bacteria as prime candidates for further study, investigating whether a persistent infection could initiate the active phase of the disease.
“If these intracellular pathogens trigger the tissue destruction observed in celiac patients,” Navasa summarized, “the digestive infection as a cause of celiac disease would cease to be a suspicion and become a new paradigm in diagnosis and treatment.”
A Novel Experimental Model Supports the Infection Hypothesis
The ULE’s advanced scientific infrastructure, including specialized animal facilities and molecular biology laboratories, has been instrumental in this research. Experiments using a murine model of “gluten enteropathy” demonstrated a critical interaction: the combination of immunity against gluten and infection with one of the identified pathogens resulted in significant tissue destruction. Crucially, neither gluten nor the infection alone produced the same level of damage.
This result strongly supports the hypothesis that infection acts as a definitive trigger, activating intraepithelial cytotoxic lymphocytes – immune cells responsible for intestinal injury. In essence, the data suggest that a digestive infection could be a crucial factor in active celiac disease, operating alongside, but not solely caused by, the autoimmune response to gluten.
Towards Treatments Beyond the Gluten-Free Diet
One of the most promising aspects of this research is its potential to inform new treatment strategies. Identifying the specific infectious agents that precipitate the disease could pave the way for therapies based on antimicrobial interventions. This approach could potentially reduce the strictness of the gluten-free diet – a challenging and often incomplete solution for many – or even replace it in certain cases, significantly improving the quality of life for those living with celiac disease.
Currently, up to 40% of adults do not experience complete recovery even while adhering strictly to a gluten-free diet, and between 1% and 2% develop refractory celiac disease, a severe complication with limited treatment options. Demonstrating a causal link between digestive infection and celiac disease would open new avenues for pharmacological intervention in these complex cases. The researchers also emphasize the difficulties associated with the gluten-free diet – its high cost, adherence challenges, and potential for nutritional deficiencies – making alternative treatments a high priority.
A Collaborative Effort with a Regional Focus
The research group, led by Navasa and Rodríguez, includes researchers Xavier Casqueiro, Miguel Ángel Ferrero, Honorina Martínez, África Sanchiz, María Isabel San Martín, Alejandro Chamizo, and Yaiza Carnicero. The project also benefits from collaborations with clinical and research teams at Mutua Terrassa Hospital, University Hospital of León, the Foundation for Biomedical Research of the San Carlos Clinical Hospital (IdISSC) in Madrid, the University of the Basque Country, and the Institute of Biomedicine and Molecular Genetics (IBGM) in Valladolid. BioDatav and Microsvet are contributing bioinformatic analysis and tissue processing expertise, further highlighting the project’s multidisciplinary and innovative nature.
As scientific understanding evolves, the ULE and the Association of Celiacs and Gluten Sensitives remain united in their commitment to better understand celiac disease and deliver more effective, personalized solutions for patients, starting with the potential of digestive infection as a cause of active celiac disease.
